Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Delayed infection exposure as a trigger for childhood ALL

Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany
Delayed infection exposure as a trigger for childhood ALL ( Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany )
24 Jun 2017

Triplet therapy for all comers in the CLL-BAG trial

Dr Paula Cramer – University of Cologne, Cologne, Germany
Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )
24 Jun 2017

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA
Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )
24 Jun 2017

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia

Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK
Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia ( Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK )
24 Jun 2017

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia

Dr Max Topp - University of Wurzburg, Wurzburg, Germany
Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
24 Jun 2017

Blood thinners a risk with cancer-associated venous thromboembolism

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada
Blood thinners a risk with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )
24 Jun 2017

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma

Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )
24 Jun 2017

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France
Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )
24 Jun 2017

Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada
Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )
24 Jun 2017

Carfilzomib combinations in ENDEAVOR and FORTE

Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
23 Jun 2017

Deep molecular response to gilteritinib in CHRYSALIS trial

Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
Deep molecular response to gilteritinib in CHRYSALIS trial ( Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA )
23 Jun 2017

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017